2ⁿᵈ Edition of the Cancer R&D World Conference 2026

Abstract

The presentation focuses on the research and development of recombinant Coxsackievirus B3 injection. Recombinant Coxsackievirus B3 injection is a genetically engineered variant of Coxsackievirus B3 used for the treatment of non-small cell lung cancer. This project has been conducted on the production process, quality, and stability of the original liquid and formulation; In vitro pharmacological studies, in vivo pharmacological studies, safety pharmacological studies, construction of BalB/c mouse myocarditis model infected with Coxsackievirus B3, single dose toxicity studies and repeated dose toxicity studies in crab eating macaques and SD rats, pharmacokinetic studies, tissue distribution studies in mice after intravenous administration, tissue distribution and virus shedding studies in tumor bearing nude mice, vascular irritation studies in rabbits, in vitro hemolysis studies, active systemic allergy studies in guinea pigs, and passive allergy studies in guinea pigs. In addition, toxicity studies of recombinant Coxsackievirus B3 injection given once intraperitoneally to BaLB/c neonatal mice were added, and the differences in pathogenicity between neonatal mice and CVB3 Nancy strain were compared.  As a conclusion, it can be confirmed that the virulence of recombinant CVB3 is significantly reduced compared to CVB3 Nancy strain, proving the successful attenuation of recombinant CVB3. The process of recombinant Coxsackievirus B3 injection is stable and the quality is controllable. Intravenous injection can effectively target tumor cells, have a significant inhibitory effect on tumors, increase the survival time of tumor bearing nude mice, and have no significant killing effect on normal cells. The safety research results show good safety, with no impact on the heart and brain, and no significant toxic side effects were found. Compared with currently marketed anti-tumor drugs and biologics, it has significant advantages.